NURS6503 extends the PMHNP's clinical competency to the unique challenges of child and adolescent psychiatry — a population where developmental stage fundamentally shapes symptom presentation, diagnostic criteria application, treatment planning, and the therapeutic relationship itself. Students learn that children are not small adults: their psychiatric conditions manifest differently, respond differently to treatment, and always exist within a family system context that adult psychiatry can sometimes bracket out.
Child and adolescent psychiatric conditions covered in NURS6503
| Diagnostic Category | Key Conditions | Developmental Considerations |
|---|---|---|
| Neurodevelopmental disorders | ADHD, autism spectrum disorder (ASD), intellectual disability, specific learning disorders, communication disorders | Diagnosis requires deviation from expected developmental trajectory, not just symptom presence; requires developmental history and often collateral information from schools |
| Mood disorders in youth | Major depressive disorder, persistent depressive disorder (dysthymia), disruptive mood dysregulation disorder (DMDD) | Pediatric depression often presents as irritability rather than sadness; DMDD distinguishes severe temper dysregulation from bipolar disorder in children |
| Anxiety disorders in youth | Separation anxiety, selective mutism, social anxiety, generalized anxiety, specific phobias, school refusal | Separation anxiety is developmentally normative until age 3–4; becomes disordered when age-inappropriate and functionally impairing |
| Trauma and stressor-related disorders | PTSD, reactive attachment disorder, disinhibited social engagement disorder, adjustment disorders | Children under 6 have separate DSM-5-TR PTSD criteria; trauma responses may manifest as behavioral regression, play reenactment, or somatic complaints rather than verbal report |
| Substance use disorders | Cannabis, alcohol, nicotine/vaping, opioid misuse in adolescents | Adolescent brain development (prefrontal cortex maturation) increases vulnerability to substance-related harm and addiction; substance use may mask underlying psychiatric conditions |
What NURS6503 covers
The course begins with developmental psychopathology — the framework that understands psychiatric conditions in children as deviations from expected developmental pathways rather than static disease states. A 7-year-old who cannot sit still in class may have ADHD, anxiety, trauma, hearing loss, or a developmentally normative activity level for their age. Accurate diagnosis requires deep understanding of what is normal at each developmental stage, what represents a concerning deviation, and how to assess the difference. NURS6503 builds this developmental lens systematically across the lifespan from infancy through late adolescence.
Assessment of children and adolescents requires multi-informant, multi-method approaches. Unlike adult psychiatry where the patient is usually the primary historian, child psychiatry draws on parent/caregiver reports, teacher observations, school records, developmental testing, standardized rating scales (Vanderbilt for ADHD, SCARED for anxiety, PHQ-A for depression), behavioral observations during clinical interviews, and the child's own self-report (which becomes more reliable with age). NURS6503 teaches students to synthesize often conflicting information — a child who is silent and withdrawn in the clinic may be aggressive and disruptive at school — into a coherent clinical formulation.
Working on a child/adolescent psychiatric case study, developmental assessment paper, or pediatric psychopharmacology analysis?
Our PMHNP writers develop child and adolescent psychiatry papers with the developmental sophistication Capella's NURS6503 rubric requires.
Key topics in NURS6503
- Developmental psychopathology: normative development vs. clinical deviation across ages
- ADHD across childhood and adolescence: assessment, multimodal treatment, stimulant management
- Autism spectrum disorder: early identification, diagnostic evaluation, comorbidity management
- Pediatric mood disorders: childhood depression, DMDD, bipolar controversy in children
- Anxiety disorders in youth: developmentally appropriate assessment and CBT-based interventions
- Pediatric psychopharmacology: FDA-approved agents, black box warnings, monitoring requirements
- Family systems assessment and intervention: family therapy integration with medication management
- Adolescent substance use: screening (CRAFFT), brief interventions, treatment approaches
- Child abuse and neglect: recognition, mandatory reporting, trauma-informed care
Pediatric psychopharmacology: critical safety considerations
- FDA black box warning: all antidepressants carry increased suicidality risk warning in children and adolescents under 25 — requires close monitoring (weekly for first 4 weeks, biweekly for 4 weeks, then monthly)
- Stimulant management: methylphenidate and amphetamine products — monitor height, weight, heart rate, blood pressure; growth velocity may decrease 1–2 cm/year during active treatment
- Atypical antipsychotics in youth: metabolic side effects (weight gain, insulin resistance, dyslipidemia) are more pronounced in pediatric patients than adults; baseline and quarterly monitoring of BMI, glucose, lipids required
- Limited FDA approvals: many psychotropics used in children lack pediatric FDA approval and are prescribed off-label — evidence base varies significantly by condition and medication
Get Help With NURS6503
Child psychiatric case studies, developmental assessments, pediatric psychopharmacology papers. Child and adolescent PMHNP coursework done right.
Place Your OrderView All ServicesRelated courses
Frequently asked questions
DMDD was introduced in the DSM-5 to address the controversy over bipolar disorder diagnosis in children. It describes children (ages 6–18) with severe, recurrent temper outbursts grossly out of proportion to the situation, occurring 3+ times per week, with a persistently irritable or angry mood between outbursts most of the day, nearly every day. DMDD was created because many children who were being diagnosed with pediatric bipolar disorder did not develop bipolar disorder as adults — they developed unipolar depression or anxiety disorders instead. DMDD captures this severe irritability pattern without applying the bipolar label and its associated treatment implications (lifelong mood stabilizers).
ADHD assessment in children is multi-method: parent interview, child interview, teacher reports (Vanderbilt or Conners rating scales completed by 2+ teachers), review of academic records, behavioral observation, and rule-out of other conditions that mimic ADHD (anxiety, trauma, sleep disorders, hearing/vision problems, learning disabilities). DSM-5-TR requires 6+ symptoms of inattention and/or hyperactivity-impulsivity, present before age 12, in 2+ settings, causing functional impairment. The PMHNP must distinguish true ADHD from anxiety-driven inattention, trauma-related hypervigilance, and developmentally normal activity levels — particularly in younger children (5–6 years) where the boundary between normal and disordered is narrowest.
CRAFFT is a validated screening tool for substance use risk in adolescents ages 12–21. The acronym stands for Car (riding with someone under the influence), Relax (using to relax), Alone (using while alone), Forget (forgetting things while using), Friends/Family (told to cut down), and Trouble (getting into trouble while using). A score of 2+ suggests problematic substance use warranting further assessment. NURS6503 teaches CRAFFT administration as part of routine adolescent psychiatric assessment because substance use commonly co-occurs with mood, anxiety, and conduct disorders in teens, and because adolescents rarely volunteer substance use information spontaneously.
Children exist within family systems — a child's psychiatric symptoms both affect and are affected by family dynamics, parenting practices, sibling relationships, parental mental health, and family stressors. Treatment that targets only the child without addressing the family context is often ineffective: a child treated for anxiety returns to an anxious, accommodating family system that reinforces avoidance; ADHD medication improves attention but cannot substitute for structure and consistency that must come from caregivers. NURS6503 teaches family assessment tools, family psychoeducation, and integration of family-based interventions with individual treatment and pharmacotherapy.